Canopy Growth Corporation
CGC Healthcare Drug Manufacturers Specialty & Generic
Canopy Growth Corporation’s revenue for fiscal 2026 (year ended March 2026) was $206.0 million, up 6.55% from fiscal 2025. In the quarter to June 2026, revenue grew 12.4%, EPS grew 87.5%, free cash flow fell 117.6% and total debt fell 18.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, operating cash flow growth for three.
Follow CGC
Canopy Growth Corporation (CGC) EV/Sales
As of 16 October 2026, Canopy Growth Corporation (CGC) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from 0.0× (December 2017) to 79.3× (October 2018); the current reading is higher than 9% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 0.9× | (20.35%) |
| FY2025 | 1.1× | (70.86%) |
| FY2024 | 3.9× | (1.96%) |
| FY2023 | 3.9× | (46.62%) |
| FY2022 | 7.4× | (73.10%) |
| FY2021 | 27.4× | 112.47% |
| FY2020 | 12.9× | (69.87%) |
| FY2019 | 42.8× | 43.25% |
| FY2018 | 29.9× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 72.36% |
| Mar 2026 | 0.9× | (37.72%) |
| Dec 2025 | 1.4× | (17.00%) |
| Sep 2025 | 1.7× | 1.84% |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BIOA BioAge Labs, Inc. compare | −9.7× |
| ACB Aurora Cannabis Inc. compare | 0.9× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| CGC Canopy Growth Corporation | 1.1× |
| KMDA Kamada Ltd. compare | 2.1× |
| ANIK Anika Therapeutics Inc. compare | 2.1× |
| LFCR Lifecore Biomedical, Inc. compare | 3.4× |
| SIGA Siga Technologies Inc. compare | 5.0× |
| TKNO Alpha Teknova, Inc. compare | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)